Our findings suggest that the upregulation of TPX2 in HCC-infiltrating CD8 + T cells improves the antitumor function of CD8 + T cells and the response to anti-PD-1 therapy through increasing the phosphorylation of P65 and activating the transcription of CXCR5 in CD8 + T cells. The gene discussed is CXCR5; the disease is hepatocellular carcinoma.